<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11970">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00529126</url>
  </required_header>
  <id_info>
    <org_study_id>SKY0402C209</org_study_id>
    <nct_id>NCT00529126</nct_id>
  </id_info>
  <brief_title>Phase 2 Dose-Ranging Study of SKY0402 for Prolonged Postoperative Analgesia in Subject Undergoing Hemorrhoidectomy</brief_title>
  <official_title>A Phase 2 Multicenter, Randomized, Double-blind, Parallel-group, Active-control, Dose-ranging Study to Evaluate the Safety and Efficacy of a Single Administration of SKY0402 for Prolonged Postoperative Analgesia in Subject Undergoing Hemorrhoidectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pacira Pharmaceuticals, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pacira Pharmaceuticals, Inc</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Republic of Georgia:</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 2 study to evaluate three dose levels of SKY0402 compared with 75 mg of bupivacaine
      HCl.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Effective postoperative pain control is a critical element in patient recovery, as the
      majority of patients may experience significant pain, particularly in the first few days
      following surgery. Appropriate postoperative pain management contributes to improved
      healing, faster patient mobilization, shortened hospital stays, and reduced healthcare
      costs.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) at Rest (NRS-R) Pain Intensity Scores From 0 Through 72 Hours</measure>
    <time_frame>0 to 72 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>To assess pain intensity at rest (NRS-R), the subject was to assume a resting position that did not exacerbate his or her postoperative pain. The subject was to rest in this position for at least 5 minutes before responding to the following question: &quot;On a scale of 0 to 10, where 0=no pain and 10=worst possible pain, how much pain are you having right now?&quot;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Participants With Adverse Events Through 72 Hours or Serious Adverse Events Through 30 Days</measure>
    <time_frame>Up to 30 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>SKY0402 high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SKY0402, single administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SKY0402 middle dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SKY0402, single administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SKY0402 low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SKY0402, single administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bupivacaine HCl</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bupivacaine HCl</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SKY0402</intervention_name>
    <description>SKY0402</description>
    <arm_group_label>SKY0402 high dose</arm_group_label>
    <arm_group_label>SKY0402 middle dose</arm_group_label>
    <arm_group_label>SKY0402 low dose</arm_group_label>
    <other_name>EXPAREL</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine HCl</intervention_name>
    <description>Bupivacaine HCl</description>
    <arm_group_label>Bupivacaine HCl</arm_group_label>
    <other_name>Marcaine 0.25% with epinephrine 1:200,000</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female, 18 years of age and older at the Screening Visit.

          2. Applies to female subjects only: Postmenopausal, surgically sterile, or willing to
             use acceptable means of contraception for at least 30 days after surgery including
             any of the following: hormonal contraceptives (e.g., oral, injectable, implantable
             starting at least 30 days before study drug administration), effective double-barrier
             methods (e.g., condoms with spermicide), intrauterine device, lifestyle with a
             personal choice of abstinence, nonheterosexual lifestyle, or a strictly monogamous
             relationship with a partner who has had a vasectomy.

          3. Scheduled to undergo 2- or 3-column excisional hemorrhoidectomy under general
             anesthesia using Milligan Morgan or Ferguson-type techniques, including modified
             approaches with specialized instruments, such as LigaSure™ or harmonic scalpel, with
             a cumulative incision length of a minimum 3 cm.

          4. American Society of Anesthesiology (ASA) Physical Class 1-3.

          5. Able and willing to comply with all study visits and procedures.

          6. Able to speak, read, and understand the language of the Informed Consent Form (ICF),
             study questionnaires, and other instruments used for collecting subject-reported
             outcomes, in order to enable accurate and appropriate responses to pain scales and
             other required study assessments.

          7. Willing and capable of providing written informed consent.

        Exclusion Criteria:

          1. Pregnancy, nursing, or planning to become pregnant during the study or within one
             month after study drug administration.

          2. Use of any of the following medications within the times specified before surgery:

               -  Long-acting opioid medication within 3 days.

               -  Any opioid medication within 24 hours.

          3. Concurrent painful physical condition that may require analgesic treatment in the
             postoperative period for pain that is not surgically related and may confound the
             postoperative assessments (e.g., rheumatoid arthritis, chronic neuropathic pain).

          4. Single-column hemorrhoidectomy or hemorrhoidectomy without an internal component.

          5. Body weight less than 50 kilograms (110 pounds).

          6. History of hypersensitivity or idiosyncratic reactions to amide-type local
             anesthetics or to opioid medication.

          7. Contraindication to epinephrine, such as concurrent administration of monoamine
             oxidase (MAO) inhibitors or antidepressants of amitriptyline or imipramine types,
             conditions where the production or exacerbation of tachycardia could prove fatal
             (e.g., poorly controlled thyrotoxicosis or severe heart disease), or any other
             pathological conditions that might be aggravated by the effects of epinephrine.

          8. Contraindications to any of the pain-control agents planned for postoperative use
             (e.g., acetaminophen [paracetamol], oxycodone, morphine, ketorolac).

          9. Administration of an investigational drug within 30 days or 5 elimination half-lives
             of such investigational drug, whichever is longer, prior to study drug
             administration, or planned administration of another investigational product or
             procedure during the subject's participation in this study.

         10. History of, suspected, or known addiction to or abuse of illicit drug(s),
             prescription medicine(s), or alcohol within the past 2 years.

         11. Uncontrolled anxiety, schizophrenia, or other psychiatric disorder that, in the
             opinion of the Investigator, may interfere with study assessments or compliance.

         12. Significant medical conditions or laboratory results that, in the opinion of the
             Investigator, indicate an increased vulnerability to study drugs and procedures, and
             expose the subject to an unreasonable risk as a result of participating in this
             clinical trial, such as: debilitating diseases, acute illnesses, hypotension, partial
             or complete conduction block, impaired cardiac function, untreated hypertension,
             advanced arteriosclerotic heart disease, cerebral vascular insufficiency,
             pre-existing abnormal neurological or neuromuscular disease (e.g., epilepsy,
             myasthenia gravis), advanced liver disease, severe renal impairment, advanced
             diabetes, comorbid conditions associated with an immunocompromised status, such as
             blood dyscrasias, HIV/AIDS, or recent chemotherapy.

             In addition, the subject will be ineligible to receive study drug if he or she meets
             the following criteria during surgery:

         13. Any clinically significant event or condition uncovered during the surgery (e.g.,
             excessive bleeding, acute sepsis) that might render the subject medically unstable or
             complicate the subject's postoperative course.

         14. A cumulative incision length less than 3 cm.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erol Onel, MD</last_name>
    <role>Study Director</role>
    <affiliation>Pacira Pharmaceuticals, Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Accurate Clinical Trials, Inc.</name>
      <address>
        <city>San Clemente</city>
        <state>California</state>
        <zip>92673</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami/Jackson Memorial</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Women's Hospital of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multicare Health Systems Laboratories</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JSC Imereti Regional Clinical Hospital of the Name A. Dzotsenidze</name>
      <address>
        <city>Kutaisi</city>
        <zip>4600</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JSC K. Eristavi National Center of Experimental and Clinical Surgery</name>
      <address>
        <city>Tbilisi</city>
        <zip>0159</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Socieety with limited responsibility Proctology Center</name>
      <address>
        <city>Tbilisi</city>
        <zip>0160</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Georgia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 3, 2013</lastchanged_date>
  <firstreceived_date>September 12, 2007</firstreceived_date>
  <firstreceived_results_date>November 23, 2011</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hemorrhoidectomy</keyword>
  <keyword>pain</keyword>
  <keyword>Postoperative</keyword>
  <keyword>analgesia</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>SKY0402 High Dose</title>
          <description>A single dose of study drug was to be administered intraoperatively via local infiltration.</description>
        </group>
        <group group_id="P2">
          <title>SKY0402 Middle Dose</title>
          <description>A single dose of study drug was to be administered intraoperatively via local infiltration.</description>
        </group>
        <group group_id="P3">
          <title>SKY0402 Low Dose</title>
          <description>A single dose of study drug was to be administered intraoperatively via local infiltration.</description>
        </group>
        <group group_id="P4">
          <title>Bupivacaine HCl</title>
          <description>A single dose of 75 mg bupivacaine was to be administered intraoperatively via local infiltration</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="24"/>
                <participants group_id="P4" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="24"/>
                <participants group_id="P4" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>SKY0402 High Dose</title>
          <description>A single dose of study drug was to be administered intraoperatively via local infiltration.</description>
        </group>
        <group group_id="B2">
          <title>SKY0402 Middle Dose</title>
          <description>A single dose of study drug was to be administered intraoperatively via local infiltration.</description>
        </group>
        <group group_id="B3">
          <title>SKY0402 Low Dose</title>
          <description>A single dose of study drug was to be administered intraoperatively via local infiltration.</description>
        </group>
        <group group_id="B4">
          <title>Bupivacaine HCl</title>
          <description>A single dose of 75 mg bupivacaine was to be administered intraoperatively via local infiltration</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="25"/>
                <measurement group_id="B2" value="25"/>
                <measurement group_id="B3" value="24"/>
                <measurement group_id="B4" value="26"/>
                <measurement group_id="B5" value="100"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
                <measurement group_id="B5" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="23"/>
                <measurement group_id="B2" value="24"/>
                <measurement group_id="B3" value="23"/>
                <measurement group_id="B4" value="25"/>
                <measurement group_id="B5" value="95"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="1"/>
                <measurement group_id="B4" value="1"/>
                <measurement group_id="B5" value="5"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="45.5" spread="11.3"/>
                <measurement group_id="B2" value="41.7" spread="11.2"/>
                <measurement group_id="B3" value="42.2" spread="11.5"/>
                <measurement group_id="B4" value="44.2" spread="10.6"/>
                <measurement group_id="B5" value="43.4" spread="11.1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
                <measurement group_id="B2" value="9"/>
                <measurement group_id="B3" value="7"/>
                <measurement group_id="B4" value="11"/>
                <measurement group_id="B5" value="30"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="22"/>
                <measurement group_id="B2" value="16"/>
                <measurement group_id="B3" value="17"/>
                <measurement group_id="B4" value="15"/>
                <measurement group_id="B5" value="70"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="5"/>
                <measurement group_id="B2" value="9"/>
                <measurement group_id="B3" value="9"/>
                <measurement group_id="B4" value="14"/>
                <measurement group_id="B5" value="37"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Georgia</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
                <measurement group_id="B2" value="16"/>
                <measurement group_id="B3" value="15"/>
                <measurement group_id="B4" value="12"/>
                <measurement group_id="B5" value="63"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) at Rest (NRS-R) Pain Intensity Scores From 0 Through 72 Hours</title>
        <description>To assess pain intensity at rest (NRS-R), the subject was to assume a resting position that did not exacerbate his or her postoperative pain. The subject was to rest in this position for at least 5 minutes before responding to the following question: “On a scale of 0 to 10, where 0=no pain and 10=worst possible pain, how much pain are you having right now?”</description>
        <time_frame>0 to 72 hours</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>SKY0402 High Dose</title>
            <description>A single dose of study drug was to be administered intraoperatively via local infiltration.</description>
          </group>
          <group group_id="O2">
            <title>SKY0402 Middle Dose</title>
            <description>A single dose of study drug was to be administered intraoperatively via local infiltration.</description>
          </group>
          <group group_id="O3">
            <title>SKY0402 Low Dose</title>
            <description>A single dose of study drug was to be administered intraoperatively via local infiltration.</description>
          </group>
          <group group_id="O4">
            <title>Bupivacaine HCl</title>
            <description>A single dose of 75 mg bupivacaine was to be administered intraoperatively via local infiltration</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                  <measurement group_id="O2" value="25"/>
                  <measurement group_id="O3" value="24"/>
                  <measurement group_id="O4" value="26"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) at Rest (NRS-R) Pain Intensity Scores From 0 Through 72 Hours</title>
            <description>To assess pain intensity at rest (NRS-R), the subject was to assume a resting position that did not exacerbate his or her postoperative pain. The subject was to rest in this position for at least 5 minutes before responding to the following question: “On a scale of 0 to 10, where 0=no pain and 10=worst possible pain, how much pain are you having right now?”</description>
            <units>units on a scale*hrs</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="175" spread="173"/>
                  <measurement group_id="O2" value="172" spread="146"/>
                  <measurement group_id="O3" value="225" spread="185"/>
                  <measurement group_id="O4" value="331" spread="175"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Adverse Events Through 72 Hours or Serious Adverse Events Through 30 Days</title>
        <time_frame>Up to 30 days</time_frame>
        <safety_issue>Yes</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>SKY0402 High Dose</title>
          <description>A single dose of study drug was to be administered intraoperatively via local infiltration.</description>
        </group>
        <group group_id="E2">
          <title>SKY0402 Middle Dose</title>
          <description>A single dose of study drug was to be administered intraoperatively via local infiltration.</description>
        </group>
        <group group_id="E3">
          <title>SKY0402 Low Dose</title>
          <description>A single dose of study drug was to be administered intraoperatively via local infiltration.</description>
        </group>
        <group group_id="E4">
          <title>Bupivacaine HCl</title>
          <description>A single dose of 75 mg bupivacaine was to be administered intraoperatively via local infiltration</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Rectal hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Executive Medical Director</name_or_title>
      <organization>Pacira Pharmaceuticals, Inc.</organization>
      <phone>203-837-6500</phone>
      <email>ErolOnel@pacira.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
